Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US Lymphoma CAR-T Consortium

Authors

Michael D Jain, Moffitt Cancer Center
Miriam T Jacobs, Washington University School of Medicine in St. Louis
Feng Gao, Washington University School of Medicine in St. Louis
Armin Ghobadi, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2-27-2024

Volume

8

Issue

4

First Page

1042

Last Page

1050

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2023011489

Rights and Permissions

Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27;8(4):1042-1050. doi: 10.1182/bloodadvances.2023011489. © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Jain, Michael D; Jacobs, Miriam T; Gao, Feng; Ghobadi, Armin; and et al., "Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US Lymphoma CAR-T Consortium." Blood Advances. 8, 4. 1042 - 1050. (2024).
https://digitalcommons.wustl.edu/oa_4/3414

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.